SCHEMBL2273122

SCHEMBL2273122

CCc1ccc(CCc2ccc(C(=O)O)c(NC(=O)c3ccccc3)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 10/20 0.57
PLK3 Q9H4B4 5/20 0.57
SLC16A3 O15427 1/20 0.57
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
PKM P14618 2/20 0.56
MAPT P10636 2/20 0.56
GRIK1 P39086 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
LTC4S Q16873 1/20 0.56
MCL1 Q07820 1/20 0.51
BCL2A1 Q16548 1/20 0.51
PPARA Q07869 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.47
ABL1 P00519 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275929 0.92 KMT2A (0.62) PLK1PLK3MEN1KMT2APKM
SCHEMBL2278451 0.88 LTC4S (0.60) PLK1PLK3MEN1KMT2APKM
SCHEMBL2271080 0.87 MEN1 (0.56) PLK1PLK3MEN1KMT2APKM
SCHEMBL2271236 0.86 PLK1 (0.60) PLK1PLK3MEN1KMT2APKM
SCHEMBL2272409 0.86 PLK1 (0.63) PLK1PLK3SLC16A3MEN1KMT2A
SCHEMBL2267959 0.86 PLK1 (0.65) PLK1PLK3SLC16A3MEN1KMT2A
SCHEMBL2274939 0.85 PLK1 (0.55) PLK1PLK3MEN1KMT2APKM
SCHEMBL2271421 0.84 DHODH (0.63) PLK1PLK3MEN1KMT2APKM
SCHEMBL2270925 0.84 PLK1 (0.57) PLK1PLK3MEN1KMT2APKM
SCHEMBL2273979 0.84 ALDH1A1 (0.58) PLK1PLK3MEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 PLK1 4227/4885PLK3 3893/4885SLC16A3 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.